JP2011502164A5 - - Google Patents

Download PDF

Info

Publication number
JP2011502164A5
JP2011502164A5 JP2010532233A JP2010532233A JP2011502164A5 JP 2011502164 A5 JP2011502164 A5 JP 2011502164A5 JP 2010532233 A JP2010532233 A JP 2010532233A JP 2010532233 A JP2010532233 A JP 2010532233A JP 2011502164 A5 JP2011502164 A5 JP 2011502164A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
peptide chain
antibody
per
composition according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010532233A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011502164A (ja
Filing date
Publication date
Priority claimed from US11/931,201 external-priority patent/US20090136505A1/en
Application filed filed Critical
Publication of JP2011502164A publication Critical patent/JP2011502164A/ja
Publication of JP2011502164A5 publication Critical patent/JP2011502164A5/ja
Pending legal-status Critical Current

Links

JP2010532233A 2007-10-31 2008-10-30 活性剤の中枢神経系への鼻内投与 Pending JP2011502164A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/931,201 US20090136505A1 (en) 2005-02-23 2007-10-31 Intranasal Administration of Active Agents to the Central Nervous System
PCT/US2008/081722 WO2009058957A2 (en) 2007-10-31 2008-10-30 Intranasal administration of active agents to the central nervous system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014126401A Division JP2014205698A (ja) 2007-10-31 2014-06-19 活性剤の中枢神経系への鼻内投与

Publications (2)

Publication Number Publication Date
JP2011502164A JP2011502164A (ja) 2011-01-20
JP2011502164A5 true JP2011502164A5 (cg-RX-API-DMAC10.html) 2011-10-06

Family

ID=40591743

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010532233A Pending JP2011502164A (ja) 2007-10-31 2008-10-30 活性剤の中枢神経系への鼻内投与
JP2014126401A Pending JP2014205698A (ja) 2007-10-31 2014-06-19 活性剤の中枢神経系への鼻内投与

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014126401A Pending JP2014205698A (ja) 2007-10-31 2014-06-19 活性剤の中枢神経系への鼻内投与

Country Status (4)

Country Link
US (3) US20090136505A1 (cg-RX-API-DMAC10.html)
EP (2) EP2207802A4 (cg-RX-API-DMAC10.html)
JP (2) JP2011502164A (cg-RX-API-DMAC10.html)
WO (1) WO2009058957A2 (cg-RX-API-DMAC10.html)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7910101B2 (en) * 2004-10-25 2011-03-22 Centocor, Inc. Melanocortin receptor binding mimetibodies, compositions, methods and uses
KR100785656B1 (ko) * 2007-05-14 2007-12-17 재단법인서울대학교산학협력재단 소염제로 사용되는 소디움글리코콜레이트 또는 그 유도체
MX2011000009A (es) * 2008-07-10 2011-08-15 Esbatech Alcon Biomed Res Unit Metodos y composiciones para la administracion mejorada de macromoleculas.
NZ599344A (en) 2009-09-25 2015-02-27 Reddy’S Lab Ltd Dr Formulations comprising triptan compounds
CN102933198B (zh) * 2009-09-25 2015-10-07 雷迪博士实验室有限公司 包含曲普坦化合物的制剂
US11337962B2 (en) 2009-09-25 2022-05-24 Upsher-Smith Laboratories, Llc Formulations comprising triptan compounds
US9539324B2 (en) 2010-12-01 2017-01-10 Alderbio Holdings, Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9067988B2 (en) 2010-12-01 2015-06-30 Alderbio Holdings Llc Methods of preventing or treating pain using anti-NGF antibodies
US9884909B2 (en) 2010-12-01 2018-02-06 Alderbio Holdings Llc Anti-NGF compositions and use thereof
US11214610B2 (en) 2010-12-01 2022-01-04 H. Lundbeck A/S High-purity production of multi-subunit proteins such as antibodies in transformed microbes such as Pichia pastoris
US9783601B2 (en) 2010-12-01 2017-10-10 Alderbio Holdings Llc Methods of preventing inflammation and treating pain using anti-NGF compositions
US9078878B2 (en) 2010-12-01 2015-07-14 Alderbio Holdings Llc Anti-NGF antibodies that selectively inhibit the association of NGF with TrkA, without affecting the association of NGF with p75
US8609088B2 (en) 2011-05-10 2013-12-17 Regents Of The University Of Minnesota Intranasal delivery of therapeutic enzymes to the central nervous system for the treatment of lysosomal storage diseases
US10016473B2 (en) 2012-08-17 2018-07-10 Howard University Method, apparatus, and kit for the pulsing treatment of neurodegenerative diseases and impairments
US9101652B2 (en) 2012-08-17 2015-08-11 Howard University Method, apparatus and kit for the treatment of neurodegenerative diseases and impairments
WO2014134070A1 (en) 2013-02-26 2014-09-04 Baxter International Inc. Treatment of central nervous system disorders by intranasal administration of immunoglobulin g
HUE044737T2 (hu) 2013-05-06 2019-11-28 Baxalta Inc Alzheimer-kór szubpopulációk kezelése egyesített immunglubulin G-vel
JP2016523835A (ja) 2013-05-15 2016-08-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ 中枢神経系へのアデノ随伴ウイルスを介した遺伝子導入
US11484574B2 (en) 2016-02-01 2022-11-01 The University Of North Carolina At Chapel Hill Polyelectrolyte complexes for delivery of agents to the CNS
US11253612B2 (en) 2016-04-15 2022-02-22 The Trustees Of The University Of Pennsylvania Gene therapy for treating mucopolysaccharidosis type II
EP3684938A1 (en) 2017-09-22 2020-07-29 The Trustees of the University of Pennsylvania Gene therapy for treating mucopolysaccharidosis type ii
EP3735298A4 (en) * 2018-01-05 2021-10-06 Impel Neuropharma Inc. INTRANASAL ADMINISTRATION OF LEVODOPA POWDER BY N BY AN OLFACTORIC PRECISION DEVICE
AU2024391694A1 (en) 2023-12-01 2026-05-21 Zhongshan Wanhan Pharmaceutical Co., Ltd. Nasal administration composition containing glp-1 receptor agonist, and preparation method therefor and use thereof

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4476116A (en) * 1982-12-10 1984-10-09 Syntex (U.S.A.) Inc. Polypeptides/chelating agent nasal compositions having enhanced peptide absorption
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
FR2598081B1 (fr) * 1986-04-30 1990-02-02 Chauvin Blache Lab Procede de preparation d'une solution pharmaceutique aqueuse d'un principe actif constitue par un acide organique
GB8823869D0 (en) * 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) * 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US5856298A (en) * 1989-10-13 1999-01-05 Amgen Inc. Erythropoietin isoforms
AU6909091A (en) 1989-12-05 1991-06-26 Ramsey Foundation Neurologic agents for nasal administration to the brain
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) * 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
GB9020544D0 (en) * 1990-09-20 1990-10-31 Sandoz Ltd Improvements in or relating to organic compounds
US5661130A (en) * 1993-06-24 1997-08-26 The Uab Research Foundation Absorption enhancers for drug administration
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
JP3597233B2 (ja) * 1993-10-21 2004-12-02 久光製薬株式会社 経鼻組成物及びそれを含有する経鼻製剤
CA2174324A1 (en) 1993-10-21 1995-04-27 Katsuya Mukae Pernasal composition and pernasal preparation containing the same
US5897858A (en) * 1994-02-03 1999-04-27 Schering-Plough Healthcare Products, Inc. Nasal spray compositions exhibiting increased retention in the nasal cavity
AU693306B2 (en) 1995-01-23 1998-06-25 Direct-Haler A/S An inhaler
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
GB9700624D0 (en) * 1997-01-14 1997-03-05 Danbiosyst Uk Drug delivery composition
IT1289608B1 (it) 1997-02-05 1998-10-15 Angelini Ricerche Spa Composizione per uso terapeutico o diagnostico somministrabile per via intranasale,sublinguale o vaginale
US6235883B1 (en) * 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6761888B1 (en) * 2000-05-26 2004-07-13 Neuralab Limited Passive immunization treatment of Alzheimer's disease
US6750324B1 (en) * 1997-12-02 2004-06-15 Neuralab Limited Humanized and chimeric N-terminal amyloid beta-antibodies
US6703381B1 (en) 1998-08-14 2004-03-09 Nobex Corporation Methods for delivery therapeutic compounds across the blood-brain barrier
US7273618B2 (en) * 1998-12-09 2007-09-25 Chiron Corporation Method for administering agents to the central nervous system
EP1135105B1 (en) 1998-12-09 2005-03-02 Chiron Corporation Use of a neurologic agent for the manufacture of a medicament for the treatment of a central nervous system disorder
WO2000033813A1 (en) 1998-12-09 2000-06-15 Chiron Corporation Administration of neurotrophic agents to the central nervous system
NZ514442A (en) * 1999-03-03 2003-08-29 Optinose As Nasal delivery device
WO2001010912A1 (en) 1999-08-09 2001-02-15 Lexigen Pharmaceuticals Corp. Multiple cytokine-antibody complexes
US6824780B1 (en) * 1999-10-29 2004-11-30 Genentech, Inc. Anti-tumor antibody compositions and methods of use
GB0007850D0 (en) 2000-03-31 2000-05-17 Microbiological Res Authority Passive and active protection against mycobacterial infections
AU2001259295A1 (en) * 2000-04-28 2001-11-12 Zengen, Inc. Method and composition for rapid delivery of bioactive compounds to the systemiccirculation via the nasal membrane
EP1345968A2 (en) * 2000-12-28 2003-09-24 Altus Biologics Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
TWI242045B (en) * 2001-03-26 2005-10-21 Cheng Technology Corp Image-directed chemical synthesis
US20040028613A1 (en) * 2001-06-25 2004-02-12 Nastech Pharmaceutical Company Inc Dopamine agonist formulations for enhanced central nervous system delivery
US20070004743A1 (en) 2002-02-25 2007-01-04 Xiao Linda L Intranasal administration of mc4-r agonists
US20040115153A1 (en) * 2002-12-17 2004-06-17 L'oreal Compositions containing at least one oil structured with at least one silicone-polyamide polymer, and at least one silicone gum and methods of using the same
US7241733B2 (en) 2002-06-28 2007-07-10 Centocor, Inc. Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
US7166575B2 (en) * 2002-12-17 2007-01-23 Nastech Pharmaceutical Company Inc. Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity
US6734427B1 (en) * 2003-02-14 2004-05-11 United Microelectronics Corp. TEM/SEM sample preparation
GB0315632D0 (en) * 2003-07-04 2003-08-13 West Pharm Serv Drug Res Ltd Pharmaceutical formulations
MX2007010244A (es) * 2005-02-23 2008-03-10 Johnson & Johnson Administracion intranasal de agentes activos al sistema nervioso central.
CA2615731A1 (en) * 2005-07-29 2007-02-08 Amgen Inc. Formulations that inhibit protein aggregation
US20090318353A1 (en) * 2006-08-25 2009-12-24 Novo Nordisk A/S Acylated Exendin-4 Compounds
WO2008049897A1 (en) * 2006-10-27 2008-05-02 Ablynx N.V. Intranasal delivery of polypeptides and proteins

Similar Documents

Publication Publication Date Title
Guo et al. Kinetic analysis of the influenza A virus HA/NA balance reveals contribution of NA to virus-receptor binding and NA-dependent rolling on receptor-containing surfaces
Waldmann et al. A nanomolar multivalent ligand as entry inhibitor of the hemagglutinin of avian influenza
JP6215223B2 (ja) マルチプレックス免疫スクリーニングアッセイ
US8900590B2 (en) Anti-hemagglutinin antibody compositions and methods of use thereof
KR20230016184A (ko) 코로나바이러스에 대한 변이체 핵산 라이브러리
US20230305002A1 (en) Protein for rapid, efficient capture of antigens
JP2019514361A5 (cg-RX-API-DMAC10.html)
CA3167318A1 (en) Polypeptides, compositions, and their use to treat or limit development of an infection
FI4074331T3 (fi) Koostumuksia ja menetelmiä entsyymien internalisoimiseksi
JP5582483B2 (ja) 一本鎖抗体、固相、遺伝子、ベクター及び宿主
JP2012525432A5 (cg-RX-API-DMAC10.html)
JP2023520468A (ja) Ａｃｅ２標的化ウイルスに対して有用な結合タンパク質
EP4206674B1 (en) High-throughput serotyping and antibody profiling assays
JP2010502207A5 (cg-RX-API-DMAC10.html)
RU2010127156A (ru) Антитела против вируса гриппа и их применение
JP2012509900A5 (cg-RX-API-DMAC10.html)
JP2009537143A5 (cg-RX-API-DMAC10.html)
Hidari et al. Chemoenzymatic synthesis, characterization, and application of glycopolymers carrying lactosamine repeats as entry inhibitors against influenza virus infection
JP2016028107A (ja) インフルエンザ感染の診断および／または処置のための組成物および方法
CN102215871B (zh) 糖结合分子
AU2018202468A1 (en) Agents for influenza neutralization
JP2023540037A5 (cg-RX-API-DMAC10.html)
AU2007332987A1 (en) Hemagglutinin polypeptides, and reagents and methods relating thereto
JP2023534922A (ja) ＳＡＲＳ－ＣｏＶ－２を標的とする抗原結合分子
US20250034235A1 (en) Compositions for preventing or treating influenza infections